Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...
GlobalData on MSN1d
Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being developed as a potential treatment for ...